Key Highlights

  • Kromek Group LSE:KMK was shown 3.87% higher on 22 September 2026, putting the company among the notable gainers in the latest market session.
  • The move comes after the company's recently released FY2026 results and management commentary on the outlook for FY2027.
  • Kromek reported FY2026 Revenue of £27.1 million, compared with £26.5 million in FY2025.
  • Underlying Advanced Imaging revenue increased strongly, while CBRN Detection revenue also recorded double-digit growth.
  • Investors are assessing whether the company's expanding order pipeline and long-term customer programmes can translate into stronger revenue and Earnings growth during FY2027.
  • The company's upcoming investor presentation on 28 September 2026 is another near-term event being watched by the market.

Why Is Kromek Group LSE:KMK in Focus on 22 September 2026?

Kromek Group LSE:KMK has moved into focus following the release of its FY2026 financial results and the company's outlook for the new financial year.

The company develops detection technologies used across two principal areas: advanced imaging and chemical, biological, radiological and nuclear detection. This gives Kromek exposure to healthcare technology as well as security and national resilience spending.

The latest results highlighted continued underlying operational growth despite a year-on-year reduction in reported profit and gross margin. Investors are now looking beyond the headline FY2026 numbers and assessing whether the company's order book, commercial pipeline and expanding customer relationships can support the growth targets outlined for FY2027.

The shares were shown up 3.87% on 22 September 2026, making the latest session an important one for a stock that has experienced considerable Volatility during September.

Why Did Kromek Group LSE:KMK Rise 3.87% Today?

The immediate catalyst for today's move appears to be the market's continued reassessment of Kromek following its FY2026 results and management's positive outlook for FY2027.

The company reported FY2026 revenue of £27.1 million, compared with £26.5 million a year earlier. Profit before tax was £2.5 million, while adjusted EBITDA was £8.1 million.

More importantly for the longer-term growth narrative, Kromek reported substantial underlying expansion in its Advanced Imaging business. Excluding certain licensing-related revenue and a non-recurring transaction, underlying Advanced Imaging revenue increased 76% to £6.7 million.

CBRN Detection revenue also increased 17% to £7.3 million, reflecting continued Demand for detection technologies used in security and national resilience applications.

These figures provide investors with evidence that the Business is generating growth outside the high-margin licensing contribution that benefited the previous year's results.

What Do Kromek's Latest Results Reveal About Its Growth?

Kromek's FY2026 results show a business undergoing a significant change in revenue composition.

Advanced Imaging generated total revenue of approximately £19.9 million, compared with £20.3 million in FY2025. However, the underlying business excluding the Enablement Agreement and a non-recurring major sale expanded substantially.

This distinction is important because licensing revenue can produce unusually high margins and create difficult year-on-year comparisons. Kromek's reported gross Margin declined to 62.8% from 80.9%, primarily because of the different revenue mix.

The underlying operating trajectory was stronger than the headline revenue number suggests. Long-term customer contracts continued to generate deliveries, while new orders added to the commercial pipeline.

The company also reported continued progress with major original equipment manufacturers in next-generation medical imaging.

Could CBRN Detection Become a Larger Growth Driver?

CBRN Detection is another important part of the Kromek Investment story.

Revenue from the division increased 17% to £7.3 million in FY2026. Management has pointed to increasing international attention on national security and the need for technologies capable of detecting chemical, biological, radiological and nuclear threats.

Kromek has also secured an initial order under a UK government radiological and nuclear detection framework.

For investors, the significance of this business extends beyond one contract. Government and security-related programmes can involve multi-year procurement cycles, creating the possibility of recurring demand if Kromek successfully converts its pipeline into additional orders.

The company has also continued investing in Manufacturing capacity, automation and intellectual property.

What Is the FY2027 Outlook for Kromek Group LSE:KMK?

Management has entered FY2027 with what it describes as positive momentum, supported by a healthy order book and commercial pipeline.

The company expects significant revenue growth across both divisions. Market expectations discussed alongside the results put FY2027 revenue at approximately £30 million, with non-licensed revenue expected to increase substantially.

The shift toward higher non-licensed revenue is particularly important because it could make the company's reported performance more representative of underlying customer demand rather than being heavily influenced by individual licensing arrangements.

Investors will therefore be watching quarterly order intake, customer deliveries, gross margin development and cash generation as the financial year progresses.

Why Is Kromek's Advanced Imaging Business Important?

Advanced Imaging remains the company's largest business and provides exposure to medical technology markets.

Kromek supplies technologies used in imaging applications and has relationships with major industry participants. The company has highlighted renewed customer engagement and continued delivery under long-term contracts.

The underlying revenue growth reported for FY2026 suggests that customer activity is strengthening, although investors will want to see whether this growth can be sustained.

The company's exposure to next-generation medical imaging also provides a potential avenue for longer-term expansion as healthcare providers and equipment manufacturers continue developing more advanced imaging systems.

What Should Investors Watch Next for Kromek Group LSE:KMK?

The next notable corporate event is Kromek's scheduled investor presentation on 28 September 2026.

Investors may use that event to seek further clarity around the FY2027 outlook, customer programmes, the order pipeline, margin expectations and the timing of revenue recognition.

The company's Balance Sheet will also remain important. Kromek ended FY2026 with £4.2 million of cash, while borrowings stood at approximately £5.7 million. The company had also secured a revolving Credit Facility and subsequently negotiated an additional extension to support working-capital requirements.

Cash conversion and working-capital management could therefore remain significant factors as the business scales.

What Is the Main Kromek Group LSE:KMK Stock Story on 22 September 2026?

The 3.87% rise in Kromek Group LSE:KMK on 22 September 2026 comes as investors continue digesting the company's FY2026 results and the outlook for FY2027.

The central issue is the contrast between weaker headline margins caused by the changing revenue mix and strong underlying growth across key operating areas. Advanced Imaging's underlying revenue growth and the 17% increase in CBRN Detection revenue provide important indicators of expanding activity.

At the same time, investors will need to monitor whether the company's order pipeline converts into revenue, whether margins stabilise as the revenue mix changes and whether increased working-capital requirements remain manageable.

The upcoming September investor presentation could provide further detail on these issues and therefore represents an important near-term event for the Kromek share-price story.

Top of Form

Bottom of Form